VISTA as a myeloid-centered checkpoint axis in cancer: biology, tumor microenvironment, and therapeutic implications
- 15 September 2026
- journal article
- review article
- Published by Springer Nature in Medical Oncology
- Vol. 43 (10) , 280
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Discovery of bifunctional small molecules targeting PD-L1/VISTA with favorable pharmacokinetics for cancer immunotherapyBioorganic Chemistry, 2025
- Impact of Doxorubicin and Docetaxel on Immune Checkpoint Expression in Colorectal Cancer: Insights into Chemotherapy Resistance MechanismsBiochemical Genetics, 2024
- Expression and function of VISTA on myeloid cellsBiochemical Pharmacology, 2024
- Repositioning baloxavir marboxil as VISTA agonist that ameliorates experimental asthmaCell Biology and Toxicology, 2024
- Chemotherapy induces immune checkpoint VISTA expression in tumor cells via HIF-2alphaBiochemical Pharmacology, 2023
- A small molecule inhibitor of VSIG-8 prevents its binding to VISTAInvestigational New Drugs, 2022
- Exploring the VISTA of microglia: immune checkpoints in CNS inflammationJournal of Molecular Medicine, 2020
- Blockade of Lymphangiogenesis Shapes Tumor-Promoting Adipose Tissue InflammationThe American Journal of Pathology, 2019
- Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumorsCancer Immunology, Immunotherapy, 2018
- Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinomaCancer Immunology, Immunotherapy, 2017